Ajanta Explains FDA Sildenafil Action, Shares Rebound
Executive Summary
Ajanta Pharma regained some lost ground on Indian bourses after the company clarified its position on an FDA import alert against its sildenafil citrate product and reported a healthy set of earnings for the third quarter ended December 2016.